Introduction
Chronic heart failure (CHF) is characterized by activation of the sympathetic nervous system (SNS) and the reninangiotensin system (RAS). It is already well known that there are interactions between the SNS and the RAS. A local RAS exists in the lung, and the pulmonary vascular endothelium is the predominant site for the angiotensinconverting enzyme which produces angiotensin II (Ang II). As a highly selective angiotensin II receptor blocker (ARB), olmesartan can not only block the combination between Ang II and the Ang II type 1 receptor (AT 1 R), but can also reduce the level of Ang II. 1 Olmesartan can reduce the activity of the RAS in CHF. In contrast, α 1Aadrenoceptor (AR) and β 2 -AR are the main adrenergic receptor subtypes in the lung and play important roles in smooth muscle contraction and relaxation, as well as alveolar fluid clearance. [2] [3] [4] [5] [6] The enhanced SNS activation in CHF can lead to down-regulation of cardiac β-AR expression. 7 However, there is little research to show that AR expression changes correspondingly under the condition of CHF, or whether olmesartan has an impact on lung AR through interactions between the RAS and the SNS. This study was designed to investigate the effect of olmesartan on heart function, levels of plasma renin activity (PRA) and Ang II, and α 1A -AR, β 1 -AR and β 2 -AR expression in the lungs of rats with CHF.
Experiment protocol
The CHF model was established by ligation of the left anterior descending artery (LAD) as previously described. 8 In brief, Wistar rats were anesthetized by intra-abdominal injection of 1% phenobarbital sodium on a volume-cycled ventilator for small animals. A high frequency and low tidal volume ventilation method (VT 10 ml/kg, respiratory rate 80 per minute, I/E ratio 1:2) was used. The rats were orotracheally intubated and the ventilation sustained from the rats anesthetized to the surgery completed. The trachea cannulas were unplugged after the rats were awake. Anterior myocardial infarction was created by ligation of the LAD. During surgery, the presence of a myocardial infarction was assessed using a 12-lead electrocardiogram. Only rats with electrical evidence of myocardial infarction were kept in the study. Four weeks later, left ventricular ejection fraction (LVEF) was evaluated by echocardiography. Rats with LVEF ≤45% were used as CHF models. 9 Rats were randomly assigned to a normal control group (normal, n = 10), or a sham-operated group (sham, n = 10). The sham group was subjected to the same procedure except for the ligation of the LAD. Rats with CHF (LVEF ≤45%) were randomly assigned to one of two groups: a CHF saline control group (CHF, n = 10) or an olmesartan group (Olm, n = 10). Rats in the normal, sham and CHF groups received an intragastric administration of saline once daily; the Olm group received an intragastric administration of olmesartan (1 mg/kg in 2 ml) saline once daily. The olmesartan dose was established according to the ratio between animal and human body surface area. The treatment lasted for 8 weeks. Ten rats from the normal and sham groups were randomly chosen to match the number of rats in the CHF and Olm groups for quantitative real-time PCR and western blotting. All surviving rats were assessed by echocardiography before and after treatment, while PRA and Ang II levels were detected by radioimmunoassay.
Echocardiography
After being anesthetized by an intra-abdominal injection of 1% pentobarbitol sodium (30 mg/kg), the rats were assessed using a 10-MHz phased-array transducer (Siemens, Germany) at a left 30° decubitus position. Two-dimensional parasternal long-and short-axis views were obtained at the papillary muscle level. Left ventricular ejection fraction, left ventricular end diastolic dimension (LVEDD), and left ventricular end systolic dimension (LVESD) were measured. All measurements, performed by an experienced technician who did not know the treatments, were averaged over three consecutive cardiac cycles.
Radioimmunoassay and tissue preparation
After rats had been anesthetized as described above, 2 ml of blood were obtained from the abdominal aorta, collected into ice-cooled anticoagulant tubes (containing 20 µl ethylene-diaminetetraacidic acid (EDTA), 10 µl 2-mercaptoethanol, and 20 µl 8-hydroxy quinoline), centrifuged at 20000× g for 10 min at 4°C and stored at −80°C. After extraction, plasma samples were directly tested by homogeneous competition radioimmunoassay using the radioimmunoassay kits for PRA and Ang II mentioned above, and then measured using a γ-radioimmunoassay counter after being centrifuged at 3000× g for 15 min at 4°C.
After taking blood samples from the abdominal aorta, the thorax was opened. Lung tissue for quantitative realtime PCR and western blotting was snap-frozen in liquid nitrogen and stored at −80°C until analysis.
Microscopic structure inspection
The lungs were filled with 10% formalin for at least 24 h before paraffin embedding and sectioning (4 µm). Sections were stained with hematoxylin-eosin. The tissues were examined using an Olympus DP70 microscope (Olympus, Tokyo, Japan). Forty histological fields (×40 magnification) were analyzed from at least four separate samples. A strict protocol for blinding and randomization was adhered to, including randomly choosing 10 sections from each mouse and selecting the most typical images to present in the results.
RNA preparation, reverse transcription, and quantitative real-time PCR
Total RNA extraction, reverse transcription-PCR and quantitative real-time PCR were performed as previously described, 9 using Trizol reagent, an RT-PCR kit and a SYBR Green Real-Time PCR kit. The PCR primer sequences are described in Table 1 . The housekeeping gene GAPDH was used as a control. Each sample was tested in triplicate. The results were normalized against GAPDH and expressed as fold change using the 2 −ΔΔCT method. 10 
Protein preparation and western blotting
Samples were homogenized in RIPA buffer (50 mM Tris/ HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1% SDS) and total protein was extracted from the homogenates. The protein concentration of the lung was quantified using the Bradford protein assay. Proteins were resolved on a 10% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE), transferred to a nitrocellulose filter membrane using a semi-dry electrophoretic graphite electrode with constant electric current of 1 mA/cm 2 gel for 2 h. Membranes were blocked with 5% nonfat dry milk in Tris-buffered saline-Tween (TBST) (20 mM Tris, 500 mM NaCl, pH 7.5, 0.1% Tween 20) at room temperature for 2 h, then incubated overnight at 4°C with diluted primary antibodies in 5% nonfat milk in TBST. The dilutions of the specific antibodies for receptor subtypes were as follows: α 1A -AR, 1:200; β 1 -AR, 1:200; β 2 -AR, 1:100. The membranes were washed three times with TBST at room temperature and then incubated with horseradish peroxidase-conjugated secondary antibody (β-actin was used as an internal standard). AB chromogenic agent (Santa Cruz Biotechnology, Inc.) was applied to the membrane for development of the film, and a scanner was used for imaging. Densitometry was applied to the analysis of protein level. The results of western blot analysis were quantified by measuring the relative intensity compared with the control using Quantity One 4.6 (Bio-Rad, Hercules, CA, USA). Ratio of signal intensity of objective strips together with intra-reference strips (β-actin) represented expressed levels of objective receptors in tissues. SPSS 17 .0 was used for statistical analysis. Data are presented as mean ± standard deviation (SD) for all assays. Statistical significance was estimated by one-way analysis of variance (ANOVA) followed by a Newman-Keuls test for comparison. A value of p < 0.05 was considered statistically significant.
Statistical analysis

Results
Apart from early death within the first 24 h after operation, one rat in CHF group died during the treatment period.
Effects of olmesartan on heart function
There was no statistically significant difference in the LVEF between the normal and sham groups before therapy (p > 0.05). Compared with the sham group, LVEF of the CHF and Olm groups was dramatically decreased (p < 0.01, p < 0.05,), whereas LVEDD and LVESD were significantly increased (p < 0.01, p < 0.05). After therapy, compared with the CHF group, LVEF of the Olm group was clearly increased (p < 0.05), while LVEDD and LVESD were decreased (p < 0.05; Table 2 ).
Effects of olmesartan on serum PRA and Ang II levels
There were no differences in PRA or Ang II between the normal and sham groups. Compared with the sham group, PRA and Ang II of rats in the CHF group were significantly increased (p < 0.01), but PRA and Ang II in the Olm group were lower than in the CHF group (p < 0.05; Table 3 ).
Effects of olmesartan on pulmonary structure
In comparison with the sham group, the pulmonary structure was remodeled in rats in the CHF group: thickening of Table1. Primer sequences used in quantitative real-time PCR reactions for α 1A -AR and β-AR subtypes.
Target
Forward primers (5'-3') Reverse primers (5'-3') Annealing temperature(°C) the alveolar septa, cellular proliferation and infiltration of inflammatory cells were all observed. The pulmonary structure remodeling was improved in the Olm group (Figure 1 ).
Effects of olmesartan on α 1A -AR, β 1 -AR and β 2 -AR mRNA levels
Expression of α 1A -AR, β 1 -AR and β 2 -AR mRNA in the normal and sham groups showed no difference (p > 0.05). Compared with the sham group, the expression of α 1A -AR and β 1 -AR mRNA was markedly decreased in the CHF group (p < 0.05); while β 2 -AR mRNA expression did not change (p > 0.05). After administration of olmesartan, mRNA expression of all three AR subtypes was significantly increased (p < 0.05; Figure 2 ).
Effects of olmesartan on α 1A -AR, β 1 -AR and β 2 -AR protein levels
Compared with the sham group, the protein expression of α 1A -AR and β 1 -AR was markedly decreased in the CHF group (p < 0.05). The protein expressions of α 1A -AR, β 1 -AR and β 2 -AR were significantly increased in the Olm group compared with the CHF group (p < 0.05) (Figure 3 ).
Discussion
The main findings of our study are: (1) Olmesartan can improve heart function and pulmonary remodeling in rats with CHF; (2) CHF was associated with increased PRA and Ang II levels, which can be inhibited by olmesartan; and (3) the levels of α 1A -AR and β 1 -AR mRNA and protein expression in the lung were down-regulated in CHF, while the mRNA and protein expressions of α 1A -AR, β 1 -AR and β 2 -AR were enhanced by olmesartan. These results indicate that olmesartan may play a beneficial role in the protection of lung in CHF by up-regulating the expression of AR and decreasing levels of PRA and Ang II. Activation of the SNS and the RAS are pathophysiological consequences of CHF. PRA and Ang II levels would be elevated after RAS activation, and Ang II could promote lung injury by stimulating the release of inflammatory cytokines, generating reactive oxygen species and accelerating fibrosis. 11 Furthermore, the lungs are very sensitive to the vasoconstrictive and proliferative effects of Ang II. A previous study reported the protective effect of irbesartan on lung remodeling in rats with CHF. 12 However, most ARBs increase PRA and Ang II levels because of the lack of negative feedback on renin activity. Some studies have reported that long-term treatment with olmesartan in hypertension resulted in decreased plasma levels of Ang II. 1, 13 However, there are very few studies concerning the effect of olmesartan on Ang II in CHF. AR also participates in the regulation of lung function, and α 1A -AR and β 2 -AR are the main AR subtypes in rat lung. α 1A -AR mediates contraction of lung vessels and hyperplasia of vascular smooth muscles, while β 2 -AR mediates bronchial smooth muscle relaxation and alveolar fluid clearance, and has anti-inflammatory action. [2] [3] [4] [5] [6] Notably, β 2 -AR plays a very important role in regulating lung function in CHF, and in other diseases. 14, 15 In our study, there was a decrease in PRA and Ang II levels and an improvement of heart function after administration of olmesartan, which is consistent with some previous studies. 1, 13, 16, 17 One possible mechanism is that olmesartan activation of angiotensin-converting enzyme 2 (ACE2) can hydrolyze Ang II to Ang1-7. Increased Ang1-7 and decreased Ang II showed a beneficial effect on ventricular remodeling and improve heart function. 18 In the present study, we found that pulmonary structure remodeling and inflammation were improved after administration of olmesartan. This is entirely consistent with a report by Jasmin et al. 12 We speculate that this result is associated with the down-regulation of Ang II by olmesartan. Furthermore, the protective effect of olmesartan on heart function might help to reduce lung injury.
Our previous study showed that expression of α 1 -AR and β-AR subtypes was altered in the heart of rats with CHF. 19 In this study, we also found changes in the lung, with α 1A -AR being down-regulated in the lung tissue of rats with CHF. When CHF occurs, the development of pressure or volume overload of the lung microcirculation elicits adaptions. It increases the resistance of gas transfer, disorders of fluid filtration and reabsorption, and alveolar membrane remodeling. 20 Down-regulation of α 1A -AR can relax the pulmonary artery and inhibit the proliferation of vascular smooth muscle, which may delay the development of pulmonary hypertension and protect the function of the right ventricle. The expression level of β 2 -AR was not down-regulated in the lungs of rats with CHF, which could be helpful for the relaxation of vascular and bronchial smooth muscles, and promotion of clearance of pulmonary edema fluid through regulation of sodium ion channels and release of inflammatory factors. 20, 21 Therefore, it had a beneficial effect in reducing pulmonary edema and improving pulmonary micro vascular permeability in CHF. 14, 22 These changes may therefore be adaptive reactions. The SNS would be activated in CHF and the elevated catecholamine could down-regulate β-AR by activating β-adrenergic receptor kinase and phosphorylating β-AR. 23 Therefore, the down-regulation of β 1 -AR may be a compensatory reaction to high levels of catecholamine in CHF.
It is generally accepted that there are extensive interactions between the SNS and the RAS. Our results showed that α 1A -AR, β 1 -AR and β 2 -AR protein expression was up-regulated after administration of olmesartan. Some data suggest that Ang II can modify the expression of α 1 -AR. 24 ,25 α 1 -AR tends to become more sensitive to agonists owing to an elevated Ang II level, which promotes alpha-adrenergic vasoconstriction. 26 The downregulation of α 1A -AR in CHF lung might be associated with the elevated Ang II level. While olmesartan reduced the Ang II level, α 1A -AR expression returned to normal levels. β 1 -AR expression was down-regulated in CHF lung. This is in good agreement with some studies, which reported that Ang II can decrease the expression level of β 1 -AR by acting on AT 1 R and then inhibiting adenylate cyclase activity; this effect could be inhibited by AT 1 R antagonists or adenylate cyclase inhibitors. 27, 28 After the Ang II level was decreased, β 1 -AR expression levels also returned to normal. However, β 2 -AR expression was not down-regulated in the current study. Similar data have been reported, in which β 2 -AR expression had not fundamentally changed in the heart of rats with CHF; β 2 -AR function had been desensitized in CHF to protect the organ. 15, 19 After treatment with olmesartan, the expression of β 2 -AR was up-regulated, which could better protect the lung function of rats with CHF. These mechanisms require further research.
Conclusion
Olmesartan can decrease levels of PRA and Ang II and regulate the expression of α 1A -AR, β 1 -AR and β 2 -AR, which may improve heart function and protect the lung.
